ANALYSIS OF VACCINE AND ANTITOXIN PRODUCTION ALTERNATIVES

File: 110596_sep96_decls19_0002.txt
Page: 0002
Total Pages: 2

Subject: ANALYSIS OF VACCINE AND ANTITOXIN PRODUCTION  ALTERNATIVES      

Unit: OTSG        

Parent Organization: HSC         

Box ID: BX003203

Folder Title: INFORMAL STUDY GUIDANCE FOR COST BENEFIT ANALYSIS                                               

Document Number:          1

Folder SEQ  #:         79








             Threat and Scenarios


                     From the sludy's inception arid dmughout the conduct of analysis, the @ and         os
             should be coo         with the Joint Staff and the Def@ Intelhgence Agency (IM-AS).
             principal, existing authoritative sources of information conceniing the d=t and scenarios are the
             Defense           Guidance (DPG). the OPALS Cqmne System @at Asmment Report (STAR),
             @ the BMDO-produced, DIA-validated GPALS Scmario Description Documents (e.g., GPALS Non-
             Campaign n=t Scenarios 91-2 and Desert Storm Campaign 91-3).

                     @ report should describe the ffi= in terms of the most likely and most ledud bacterial
             agents and @ to be employed @ U.S. forces. Mz report should desen'be the curmu vaccines
             and antitoxins avaDaNUty dumgh existing commercial           =m.          vaccine and antitoxin
             smkpiles, ease of producdm and levels of effectiveness.

             Mission Analysis

                     A mission analysis should be performed that determines the extent to which the candidate
             alternatives am able to meet the @mments, critical dmsholds, and performance objectives set fordi
             in the applicable requirements documents. Mz @ysis should consider a range Qf contingmdes
             from limited acts of terroz @theat                      SrA

             Measures of Effectivenes
                     The study shoul& Jer ae                                         $-describe fuuy the mwtary
             worth of aU the alternative          -',I--'niL @ following constitute the minimum set of MOEs
             applicable vaccine and antitoxin production alternatives:

                            Number of type of vaccines and antitoxins produced.

                            Quantity of each type of vaccine and antitoxin pmduced.

                            Storage c@Wty.

                            Production surge capability.

                     0      L4egal implications (uwemnificadon, FDA approval).

                     0              on fleximty.

                     0      Dual-use (joim effort wah otber medical organizations).

             Cost Analysis

                     For eacb alternative, provide an estimate of Ut cycle costs for a 20-year openft period.
             Provide RDT&E and             erit costs for the WW Mm wO by su@m and mjhtary
             construction costs (if any) in then-year and FY94 constant doU=.         O&S costs in FY94
             odnsm doll=.

Document 2 f:/Week-36/BX003203/INFORMAL STUDY GUIDANCE FOR COST BENEFIT ANALYSIS/analysis of vaccine and antitoxin production al:11049609101920
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003203
Unit = OTSG
Parent Organization = HSC
Folder Title = INFORMAL STUDY GUIDANCE FOR COST BENEFIT ANALYSIS
Folder Seq # = 79
Subject = ANALYSIS OF VACCINE AND ANTITOXIN PRODUCTION AL
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 04-NOV-1996